Only Jot Dx ICM from Abbott puts you in complete control
Jot Dx™ Insertable Cardiac Monitor (ICM) is the latest medical technology advancement only from Abbott that helps people get back to living their best lives, faster.
Jot Dx ICM is powered by SyncUP™ - a concierge service, provided by Abbott that helps patients get connected to the myMerlin™ mobile app so that data is automatically sent to your clinic.
JOT DX INTRODUCES THE FIRST ICM TO GIVE YOU THE POWER OF CHOICE
Select between three key episodes* or all episode data and so that you can get precise and actionable data without feeling overwhelmed by data burden.
Flexibilty to match the needs of your clinic or individual patients.
Discover what Jot Dx has to offer by watching our short video below
Decrease Your Data Burden,
Increase Control
Focus your diagnostic data
Choose to view three key episodes* for a patient or facility.
Decrease your data burden on average by
With Key Episodes turned on and Jot Dx ICM pause algorithm improvements
Potential Staff Time Savings From Reduced Data Burden
All patients2
Hours/year reduction
Top 25th percentile patients2
Hours/year reduction
Manage With Flexibility to get all Episodes
For hard-to-detect arrhythmias you can toggle to view all episodes for a specific patient, rather than three key episodes. You can also view all episodes facility-wide.
Get Episode Data Unique to each arrhythmia type
Key episodes are uniquely programmed to evaluate each arrhythmia differently: AFib, Tachy, Brady and Pause each have a novel set of evaluation criteria that make up the three key episodes. This ensures you receive the most insightful data based on arrhythmia type.
Better selection criteria sets Jot Dx ICM apart from others that use a standard set of criteria for all types.
Diagnose with Confidence
Even with three key episodes turned on, there is no loss of accuracy, and virtually no delay-to-diagnosis.2
Detect With Accuracy
With Sharpsense Technology, Greater P-Wave and R-Wave Visibility Detect True Episodes.
Jot Dx ICM with SharpSense™ technology improves accuracy of all episodes by harnessing the power of extra discriminators to confirm or reject detections – significantly improving the accuracy of Atrial Fibrillation, Bradycardia and Pause detected episodes.
Relative Sensitivity
overall reduction in false positives5
Retrospective analysis of a Global Registry demonstrates SharpSense™ technology significantly reduces false detection of AFib, Bradycardia and Pause episodes.
STAY UP TO DATE WITH RECENT NEWS, PRODUCT
HIGHLIGHTS AND CASE STUDIES
References
*Key episodes is a feature of Merlin.net™
**Determined by evaluation of real-world episodes in previously identified devices, using SharpSense™ technology.
- EGM Burden Reduction in Jot Dx ICM, Technical Development Report System DOC 90805939 Rev A.
- HRS 2021 Poster - Reducing Clinical Review Burden of Insertable Cardiac Monitors In Patients with Frequent Arrhythmia Detections
- Medtronic REVEAL LINQ‡ Insertable Cardiac Monitor and Patient Assistant PA96000 Clinical Manual, 2015
- Medtronic LINQ‡ II Insertable Cardiac Monitor Clinical Manual, 2020
- Piorkowski C, Manyam H, Lakkireddy D, et al. Effectiveness and performance of Confirm Rx SharpSense Technology: A Multi-center Retrospective Analysis. Presented at Asia Pacific Heart Rhythm Society (APHRS); Bangkok, Thailand; Oct 27-29, 2019.
™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third-party trademark, which is property of its respective owner.
MAT-2108290 v3.0
Stay Connected